{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-014887","form_type":"8-K","ticker":"SOLV","cik":"0001964738","company_name":"Solventum Corp","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.325455+00:00","generated_at":"2026-06-04T02:32:32.048440+00:00","sec_items":["1.01","3.03","5.03","5.02","5.05","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Solventum completes 3M spin-off, begins trading on NYSE as SOLV","bullets":["80.1% of Solventum shares distributed to 3M stockholders on April 1, 2024; spin-off effective 3:30 a.m. ET.","Solventum reported $8.2B sales in 2023; employs 22,000 people across four business segments.","New executive team: CEO Bryan Hanson, CFO Wayde McMillan, board chair Carrie Cox.","Board reconstituted to 11 members with four committees (Audit, Governance, Talent, Science/Quality).","Separation agreements signed with 3M covering transition services, tax, IP, supply, and trademarks."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-014887","json":"https://secwatch.observer/filing/0001628280-24-014887.json","markdown":"https://secwatch.observer/filing/0001628280-24-014887.md","text":"https://secwatch.observer/filing/0001628280-24-014887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/solventum-closing8xk4324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:32:32.048440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15e280dfbf","claim":"Paul Harrington was appointed as Chief Supply Chain Officer at Solventum Corp.","evidence_excerpt":"Paul Harrington Chief Supply Chain Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Supply Chain Officer"}],"fact_type":"executive_change"},{"claim_id":"25f8083906","claim":"Marcela Kirberger was appointed as Chief Legal Affairs Officer, Corporate Secretary at Solventum Corp.","evidence_excerpt":"Marcela Kirberger Chief Legal Affairs Officer, Corporate Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Legal Affairs Officer, Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"63f3a7d7d2","claim":"Tammy Gomez was appointed as Chief Human Resources Officer at Solventum Corp.","evidence_excerpt":"Tammy Gomez Chief Human Resources Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Human Resources Officer"}],"fact_type":"executive_change"},{"claim_id":"69740a443e","claim":"Mary Wilcox was appointed as Senior Vice President, Controller and Chief Accounting Officer at Solventum Corp.","evidence_excerpt":"Mary Wilcox Senior Vice President, Controller and Chief Accounting Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Controller and Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"74bc333dc3","claim":"Amy Landucci was appointed as Chief Information and Digital Officer at Solventum Corp.","evidence_excerpt":"Amy Landucci Chief Information and Digital Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Information and Digital Officer"}],"fact_type":"executive_change"},{"claim_id":"7b578cccf5","claim":"Bryan Hanson was appointed as Chief Executive Officer at Solventum Corp.","evidence_excerpt":"Bryan Hanson Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"89c4113390","claim":"Chris Barry was appointed as Executive Vice President and Group President, Medical Solutions at Solventum Corp.","evidence_excerpt":"Chris Barry Executive Vice President and Group President, Medical Solutions","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Group President, Medical Solutions"}],"fact_type":"executive_change"},{"claim_id":"935eee1122","claim":"Wayde McMillan was appointed as Chief Financial Officer at Solventum Corp.","evidence_excerpt":"Wayde McMillan Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"acdb105364d36d2b48b3bb2e3b7a02d9857aebbc","claim":"Solventum Corp: Adoption of Corporate Governance Guidelines and Board of Directors Code of Business Conduct and Ethics.","evidence_excerpt":"In connection with the Distribution, the Board adopted Corporate Governance Guidelines and a Board of Directors Code of Business Conduct and Ethics, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"b08635f62dbe5a3f4e1a10893a2077ee26b46135","claim":"Solventum Corp: Amended and restated Certificate of Incorporation effective March 31, 2024 (effective 2024-03-31).","evidence_excerpt":"Effective as of 3:30 a.m. Eastern Time on March 31, 2024, Solventum amended and restated its Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-31"}],"fact_type":"governance_change"},{"claim_id":"b7b5e073ed3d7a0f0fade95d8c9349a438517732","claim":"Solventum Corp: Amended and restated Bylaws effective March 31, 2024 (effective 2024-03-31).","evidence_excerpt":"immediately thereafter, amended and restated its Bylaws (the “Amended and Restated Bylaws”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-03-31"}],"fact_type":"governance_change"},{"claim_id":"2bfbed701cc68174842cb84a2da4f916e2098ef8","claim":"Solventum Corp entered into Separation and Distribution Agreement and related agreements with 3M Company valued at Entry into multiple separation-related agreements including Separation and Distribution Agreement, T (effective 2024-03-31).","evidence_excerpt":"On March 31, 2024, Solventum Corporation (“Solventum”) entered into several agreements with 3M Company (“3M”) in connection with the spin-off of 3M’s health care business (the “Separation”) through the pro rata distribution of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum to 3M’s stockholders of record as of the close of business on March 18, 2024 (the “Distribution”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/0001628280-24-014887-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"3M Company"},{"label":"Value","value":"Entry into multiple separation-related agreements including Separation and Distribution Agreement, T"},{"label":"Effective","value":"2024-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}